Notice2026-19698
Foreign-Trade Zone (FTZ) 93, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Durham, North Carolina
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 25, 2026
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 185 (Friday, September 25, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 185 (Friday, September 25, 2026)]
[Notices]
[Pages 60934-60935]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19698]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-122-2026]
Foreign-Trade Zone (FTZ) 93, Notification of Proposed Production
Activity; Eli Lilly and Company; (Drug Products); Durham, North
Carolina
Eli Lilly and Company submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Durham, North Carolina within Subzone 93K. The notification conforming
to the requirements of the Board's regulations (15 CFR 400.22) was
received on September 17, 2026.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products include: Incretin-based therapy for
blood glucose and weight management drug product in dosage/packaged
form in filled syringes, vials, or delivery pens or semi-finished
syringes; CGRP monoclonal antibody for migraine prevention drug product
in dosage/packaged form in filled syringes, vials, or delivery pens or
semi finished syringes; IL-17A monoclonal antibody for chronic
inflammatory conditions drug product in dosage/packaged form in filled
syringes, vials, or delivery pens or semi-finished syringes; Incretin-
based therapy for blood glucose management in type 2 diabetes drug
product in dosage/packaged form in filled syringes, vials, or delivery
pens or semi-finished syringes; Multi-incretin therapy for weight and
metabolic management drug product in dosage/packaged form in filled
syringes, vials, or delivery pens or semi-finished syringes; IL-13-
targeted therapy for atopic dermatitis management drug product in
dosage/packaged form in filled syringes, vials, or delivery pens or
semi finished syringes; IL-23-targeted therapy for inflammatory bowel
disease management drug product in dosage/packaged form in filled
syringes, vials, or delivery pens or semi-finished syringes; Amylin
receptor-targeted therapy for weight management drug product in dosage/
packaged form in filled syringes, vials, or delivery pens or semi-
finished syringes; and Amyloid-
[[Page 60935]]
targeted therapy for early Alzheimer's disease drug product in dosage/
packaged form in filled syringes, vials, or delivery pens or semi-
finished syringes (duty free).
The proposed foreign-status materials/components include: Incretin-
based therapy for blood glucose and weight management drug substance;
Incretin-based therapy for blood glucose and weight management drug
product in vials or semi-finished syringes; CGRP monoclonal antibody
for migraine prevention drug substance; CGRP monoclonal antibody for
migraine prevention drug product in vials or semi-finished syringes;
IL-17A monoclonal antibody for chronic inflammatory conditions drug
substance; IL-17A monoclonal antibody for chronic inflammatory
conditions drug product in vials or semi-finished syringes; Incretin-
based therapy for blood glucose management in type 2 diabetes drug
substance; Incretin-based therapy for blood glucose management in type
2 diabetes drug product in vials or semi-finished syringes; Multi-
incretin therapy for weight and metabolic management drug substance;
Multi-incretin therapy for weight and metabolic management drug product
in vials or semi-finished syringes; IL-13-targeted therapy for atopic
dermatitis management drug substance; IL-13-targeted therapy for atopic
dermatitis management drug product in vials or semi-finished syringes;
IL-23-targeted therapy for inflammatory bowel disease management drug
substance; IL-23-targeted therapy for inflammatory bowel disease
management drug product in vials or semi-finished syringes; Amylin
receptor-targeted therapy for weight management drug product in vials
or semi-finished syringes; Amylin receptor-targeted therapy for weight
management drug substance; Amyloid-targeted therapy for early
Alzheimer's disease drug product in vials or semi-finished syringes;
Amyloid-targeted therapy for early Alzheimer's disease drug substance;
Medicine delivery device, and parts thereof--including Cap Cartridge
Holder, Dry Side Subassembly, Damping Cup, RNS Puller, Base Cap;
Medicine delivery device needles; Glass vials; and Syringes (duty
free).
The request indicates that certain materials/components are subject
to duties under section 232 of the Trade Expansion Act of 1962 or
section 301 of the Trade Act of 1974, depending on the country of
origin. The applicable section 232 and section 301 decisions require
subject merchandise to be admitted to FTZs in privileged foreign status
as described in 19 CFR 146.41.
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#432537390337312227266d242c35"><span class="__cf_email__" data-cfemail="731507093307011217165d141c05">[email protected]</span></a>. The closing period for their receipt is November 4,
2026.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact John Frye at <a href="/cdn-cgi/l/email-protection#2c66434442026a5e55496c585e4d4849024b435a"><span class="__cf_email__" data-cfemail="8dc7e2e5e3a3cbfff4e8cdf9ffece9e8a3eae2fb">[email protected]</span></a>.
Dated: September 22, 2026.
Colin Agostisi,
Executive Secretary.
[FR Doc. 2026-19698 Filed 9-24-26; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 25, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.